NICE turnaround for AstraZeneca’s COPD drug Daxas
AstraZeneca | June 23, 2017
The National Institute has now issued draft guidance recommending Daxas (roflumilast) in COPD patients whose disease is class as severe and when symptoms continue to worsen despite other treatments, after two new trials showed that it helped ease symptoms not under control with inhalers.